Analysis of Chinese Second-Class Vaccine Procurement Data

This document presents a technical collection, cleaning, and analysis of publicly available Chinese second‑class vaccine procurement data across provinces.

Data Sources : The author aggregated data from various government websites, covering procurement projects from 2017‑2020 for vaccines such as those listed under "第二类疫苗". Sources include provincial procurement announcements, supplier shortlists, and price catalogs. A total of 28 provincial-level regions (excluding Hong Kong, Macau, Taiwan, Shandong, Qinghai, and Tibet) were successfully gathered.

Collection Keywords used in searches included combinations of province name with terms like "第二类疫苗 采购", "第二类疫苗 公示", "第二类疫苗 产品及价格", etc.

Collected Results : The author lists each province with the corresponding source document (e.g., 北京市 – 2018‑2019免疫规划用第二类疫苗采购项目). Some provinces lacked data due to registration requirements, dead links, or missing information.

Data Cleaning : The raw data were normalized into a CSV format with columns: name, src, create_company, report_company, prov, year. The author notes that non‑XLS files required extensive manual processing.

Data Summary (CSV aggregation yields 1,529 records):

count    167.000000
mean      9.143713
std      15.839281
min       1.000000
25%       1.000000
50%       3.000000
75%       9.000000
max      98.000000

The distribution is heavily right‑skewed, with a median of 3 manufacturers per vaccine and a maximum of 98.

Top Manufacturers (by number of vaccine entries):

Manufacturer

Count

北京科兴生物制品有限公司

98

长春长生生物科技有限责任公司

91

华兰生物疫苗有限公司

72

玉溪沃森生物技术有限公司

57

上海生物制品研究所有限责任公司

56

大连雅立峰生物制药有限公司

51

长春生物制品研究所有限责任公司

50

华北制药金坦生物技术股份有限公司

46

辽宁成大生物股份有限公司

44

北京智飞绿竹生物制药有限公司

43

Provincial Share of Major Suppliers (example percentages for 14 provinces with data):

[{'name': '天津', 'value': 14.0625},
 {'name': '辽宁', 'value': 17.647058823529413},
 {'name': '黑龙江', 'value': 13.274336283185843},
 {'name': '安徽', 'value': 9.75609756097561},
 {'name': '新疆', 'value': 16.94915254237288},
 {'name': '江苏', 'value': 14.563106796116504},
 {'name': '江西', 'value': 12.179487179487179},
 {'name': '山西', 'value': 16.52173913043478},
 {'name': '吉林', 'value': 17.857142857142858},
 {'name': '贵州', 'value': 14.17910447761194},
 {'name': '广东', 'value': 13.445378151260504},
 {'name': '四川', 'value': 16.93548387096774},
 {'name': '宁夏', 'value': 17.5},
 {'name': '海南', 'value': 14.285714285714285}]

These figures show that manufacturers such as 长春长生 appear in the top‑10 share across most provinces, with red‑shaded bars indicating ~20% share and darker red indicating ~10%.

Limitations : The dataset is incomplete; several provinces (e.g., Shandong, Qinghai, Tibet) lack data, and the author spent over 14 hours manually gathering and cleaning the information. The analysis is therefore provisional and intended as a reference for further work.

Conclusion : The study demonstrates that a small number of large vaccine manufacturers dominate the Chinese second‑class vaccine market, and that publicly disclosed procurement data can be aggregated and visualized using standard data‑science tools (pandas, eCharts). The author invites continued contributions via a public GitHub repository.